Literature DB >> 25019701

3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKT-mTOR pathway thus sensitizing MDR cancer to chemotherapy.

Zhenyou Zou1, Jing Zhang, Haiyang Zhang, Huan Liu, Zhiguo Li, Dan Cheng, Jun Chen, Lu Liu, Mengjie Ni, Yu Zhang, Jun Yao, Jun Zhou, Junjie Fu, Yong Liang.   

Abstract

Multi-drug resistance (MDR) cancer is an intractable problem. Over-expression of drug efflux transporters such as ABCB1, ABCC1 and ABCG2 contributes to it, by which they pump drugs out of cells, and result in the decrease in the efficacy of chemotherapy. To reverse the cancer MDR, we used 3-methyladenine (3-MA) treatment on taxol or doxorubicin stressed MDR cell lines A2780DX5 and SGC7091R and xeno-tumor implanted mice. The results indicate that ABCB1, ABCC1 and ABCG2 were depressed, and the PI3K-AKT-mTOR pathway was blocked. Moreover, using FITC-labeled taxol as the indicator, we observed that the drug accumulation was enhanced in MDR cells and more cells were killed after 3-MA administration. Thus suggesting that 3-MA can reverse cancer MDR via depressing agent-efflux transporters.

Entities:  

Keywords:  3-Methyladenine; PI3K–AKT–mTOR pathway; drug efflux transporters; multi-drug resistance

Mesh:

Substances:

Year:  2014        PMID: 25019701     DOI: 10.3109/1061186X.2014.936870

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  6 in total

Review 1.  Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization.

Authors:  Marta Pérez-Hernández; Alain Arias; David Martínez-García; Ricardo Pérez-Tomás; Roberto Quesada; Vanessa Soto-Cerrato
Journal:  Cancers (Basel)       Date:  2019-10-19       Impact factor: 6.639

Review 2.  Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.

Authors:  Chao Dong; Jiao Wu; Yin Chen; Jianyun Nie; Ceshi Chen
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

3.  NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy.

Authors:  Hongsheng Wang; Wen Li; Jing Xu; Tao Zhang; Dongqing Zuo; Zifei Zhou; Binhui Lin; Gangyang Wang; Zhuoying Wang; Wei Sun; Mengxiong Sun; Shimin Chang; Zhengdong Cai; Yingqi Hua
Journal:  Cell Death Dis       Date:  2017-09-14       Impact factor: 8.469

4.  Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.

Authors:  Jingqiu Wang; Dong-Hua Yang; Yuqi Yang; Jing-Quan Wang; Chao-Yun Cai; Zi-Ning Lei; Qiu-Xu Teng; Zhuo-Xun Wu; Linguo Zhao; Zhe-Sheng Chen
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

5.  Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer.

Authors:  Ye Wang; Yanfang Liu; Xinyang Du; Hong Ma; Jing Yao
Journal:  Onco Targets Ther       Date:  2020-03-04       Impact factor: 4.147

6.  The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.

Authors:  Lei Zhang; Yidong Li; Qianchao Wang; Zhuo Chen; Xiaoyun Li; Zhuoxun Wu; Chaohua Hu; Dan Liao; Wei Zhang; Zhe-Sheng Chen
Journal:  Mol Cancer       Date:  2020-01-17       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.